Does Adding Magnesium Sulphate to Low Dose Rocuronium Affects Depth of Blockade

NCT ID: NCT04510337

Last Updated: 2021-03-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-02

Study Completion Date

2021-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aim is to compare the effect of magnesium sulphate combined with low dose rocuronium versus standard dose rocuronium

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Comparing the effect of magnesium sulphate combined to low dose rocuronium versus standard dose rocuronium in cancer patients undergoing direct laryngoscopy for laryngeal tumors regarding intubating conditions, intraoperative relaxation, depth of anesthesia and recovery time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard rocuronium

patients received rocuronium 0.6mg/kg

Group Type ACTIVE_COMPARATOR

standard rocuronium dose

Intervention Type DRUG

0.6 mg/kg rocuronium during induction of anesthesia

Magnesium

patients received 100 ml saline with 50mg/kg magnesium sulphate infusion over 10 minutes

Group Type EXPERIMENTAL

Magnesium sulfate

Intervention Type DRUG

50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

standard rocuronium dose

0.6 mg/kg rocuronium during induction of anesthesia

Intervention Type DRUG

Magnesium sulfate

50 mg/kg magnesium sulphate added to 0.40 mg/kg rocuronium

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

standard dose rocuronium low dose rocuronium

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with Laryngeal tumors

ASA I-II

Age 30-70 years

Exclusion Criteria

Renal and or hepatic insufficiency

Neuromuscular disease

Large glottic and/or supra-glottic lesions with or without breathing difficulties

Known allergy to any of the used drug
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute, Egypt

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Walaa Youssef Elsabeeny

Lecturer of anesthesia and pain management

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Walaa Y Elsabeeny, MD

Role: PRINCIPAL_INVESTIGATOR

Lecturer

Mohamed A Wadod, MD

Role: STUDY_DIRECTOR

Lecturer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Cancer Institute

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201617031.2P

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.